KZA 0.00% 8.0¢ kazia therapeutics limited

Ann: Kazia licenses EVT801 from Evotec, page-10

  1. 114 Posts.
    lightbulb Created with Sketch. 125
    I think it is excellent news.
    It’s another area of unmet need, recurrent solid tumors, and the pre-clinical data, especially the synergistic properties with immune checkpoint therapies is exciting!

    The initial financial investment is fairly small and it says a lot about Kazia’s reputation and business development team that they were chosen as global partner.


 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.